Literature DB >> 25548440

The Prognostic Relevance of BAALC and ERG Expression Levels in Cytogenetically Normal Pediatric Acute Myeloid Leukemia.

Salah Aref1, Tawfik Al Khodary2, Tarek Abou Zeed3, Amre El Sadiek1, Nadia El Menshawy1, Rasha Al Ashery4.   

Abstract

UNLABELLED: Cytogenetic aberrations are important prognostic factors in acute myeloid leukemia (AML). About 45 % of de novo adult AML and 20 % of pediatric AML lack cytogenetic abnormalities, so identification of predictive molecular markers might improve therapy. Mutation status of FLT3, NPM1 genes and gene expression levels of ERG, BAALC have been postulated as possible prognostic markers in pediatric AML with normal karyotype. Pretreatment blood samples from 47 cytogenetically normal AML patients were analysed for BAALC and ERG expression using real time RT-PCR. The patients were dichotomized at BAALC and ERG mean expression into low and high expression based on the median expression as cutoff. BAALC showed high expression in (24/47; 51.1 %) of patients and ERG high expression was detected in (22/47; 46.6 %). With follow-up for 1 year, patients with high BAALC and high ERG had inferior EFS (P = 0.001, P = 0.017 respectively), overall survival (P = 0.001, 0.08 respectively), and low rates of induction remission (P = 0.001, P = 0.0017 respectively) as compared to those with low expression. Also there was significant positive association between high expression of BAALC; ERG and FLT-ITD mutations (P = 0.016; P = 0.007 respectively). Multivariable analysis confirmed that high BAALC expression is an independent risk factor for EFS [HR for EFS 1.9(1.04-3.46) P = 0.037]; and OS [HR OS 1.55(1.7-3.36) P = 0.03]. IN
CONCLUSION: Over expression of BAALC could predict adverse clinical outcome and may define important risk factor in cytogenetically normal pediatric AML.

Entities:  

Keywords:  BAALC; CN-AML; ERG; Prognosis

Year:  2014        PMID: 25548440      PMCID: PMC4275528          DOI: 10.1007/s12288-014-0395-z

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  28 in total

1.  CD200 as a prognostic factor in acute myeloid leukaemia.

Authors:  A Tonks; R Hills; P White; B Rosie; K I Mills; A K Burnett; R L Darley
Journal:  Leukemia       Date:  2007-01-25       Impact factor: 11.528

2.  The clinical relevance of BAALC and ERG expression levels in pediatric AML.

Authors:  M C H Hermkens; M M van den Heuvel-Eibrink; S T C J M Arentsen-Peters; A Baruchel; J Stary; D Reinhardt; M Zimmerman; V de Haas; R Pieters; C M Zwaan
Journal:  Leukemia       Date:  2012-08-16       Impact factor: 11.528

3.  Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Authors:  Heiko Becker; Guido Marcucci; Kati Maharry; Michael D Radmacher; Krzysztof Mrózek; Dean Margeson; Susan P Whitman; Peter Paschka; Kelsi B Holland; Sebastian Schwind; Yue-Zhong Wu; Bayard L Powell; Thomas H Carter; Jonathan E Kolitz; Meir Wetzler; Andrew J Carroll; Maria R Baer; Joseph O Moore; Michael A Caligiuri; Richard A Larson; Clara D Bloomfield
Journal:  Blood       Date:  2010-05-04       Impact factor: 22.113

4.  Clinical implications of angiogenic factors in patients with acute or chronic leukemia: hepatocyte growth factor levels have prognostic impact, especially in patients with acute myeloid leukemia.

Authors:  Jong Gwang Kim; Sang Kyun Sohn; Dong Hwan Kim; Jin Ho Baek; Nan Young Lee; Jang Soo Suh; Shung-Chull Chae; Kun Soo Lee; Kyu Bo Lee
Journal:  Leuk Lymphoma       Date:  2005-06

Review 5.  Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?

Authors:  Krzysztof Mrózek; Guido Marcucci; Peter Paschka; Susan P Whitman; Clara D Bloomfield
Journal:  Blood       Date:  2006-09-07       Impact factor: 22.113

6.  Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.

Authors:  Konstanze Döhner; Richard F Schlenk; Marianne Habdank; Claudia Scholl; Frank G Rücker; Andrea Corbacioglu; Lars Bullinger; Stefan Fröhling; Hartmut Döhner
Journal:  Blood       Date:  2005-07-28       Impact factor: 22.113

7.  BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Authors:  Sebastian Schwind; Guido Marcucci; Kati Maharry; Michael D Radmacher; Krzysztof Mrózek; Kelsi B Holland; Dean Margeson; Heiko Becker; Susan P Whitman; Yue-Zhong Wu; Klaus H Metzeler; Bayard L Powell; Jonathan E Kolitz; Thomas H Carter; Joseph O Moore; Maria R Baer; Andrew J Carroll; Michael A Caligiuri; Richard A Larson; Clara D Bloomfield
Journal:  Blood       Date:  2010-09-14       Impact factor: 22.113

8.  Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.

Authors:  Christian Langer; Guido Marcucci; Kelsi B Holland; Michael D Radmacher; Kati Maharry; Peter Paschka; Susan P Whitman; Krzysztof Mrózek; Claudia D Baldus; Ravi Vij; Bayard L Powell; Andrew J Carroll; Jonathan E Kolitz; Michael A Caligiuri; Richard A Larson; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

9.  BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study.

Authors:  Claudia D Baldus; Stephan M Tanner; Amy S Ruppert; Susan P Whitman; Kellie J Archer; Guido Marcucci; Michael A Caligiuri; Andrew J Carroll; James W Vardiman; Bayard L Powell; Steven L Allen; Joseph O Moore; Richard A Larson; Jonathan E Kolitz; Albert de la Chapelle; Clara D Bloomfield
Journal:  Blood       Date:  2003-05-15       Impact factor: 22.113

10.  ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays.

Authors:  Klaus H Metzeler; Annika Dufour; Tobias Benthaus; Manuela Hummel; Maria-Cristina Sauerland; Achim Heinecke; Wolfgang E Berdel; Thomas Büchner; Bernhard Wörmann; Ulrich Mansmann; Jan Braess; Karsten Spiekermann; Wolfgang Hiddemann; Christian Buske; Stefan K Bohlander
Journal:  J Clin Oncol       Date:  2009-09-14       Impact factor: 44.544

View more
  2 in total

Review 1.  E-26 Transformation-specific Related Gene Expression and Outcomes in Cytogenetically Normal Acute Myeloid Leukemia: A Meta-analysis.

Authors:  Jian-Fei Fang; Hai-Ning Yuan; Yong-Fei Song; Pei-Bei Sun; Xiao-Liang Zheng; Xiao-Ju Wang
Journal:  Chin Med J (Engl)       Date:  2017-06-20       Impact factor: 2.628

2.  A novel scoring system for acute myeloid leukemia risk assessment based on the expression levels of six genes.

Authors:  Xiaoyan Zhao; Yuan Li; Haibing Wu
Journal:  Int J Mol Med       Date:  2018-06-21       Impact factor: 4.101

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.